Director Declaration

GlaxoSmithKline PLC
14 January 2004

                GlaxoSmithKline plc Executive Director's details

Further to the announcement dated 15 December 2003, the following details for Dr
Tadataka (Tachi) Yamada are provided in accordance with the requirements of the
Financial Services Authority's Listing Rules on his appointment to the Board of
GlaxoSmithKline plc with effect from 1 January 2004.

The following table shows Dr Yamada's current and past directorships of publicly
quoted companies during the past five years.



        Company                       Country of incorporation

Current directorships

diaDexus, Inc.                        USA

Past directorships

SmithKline Beecham p.l.c.             England & Wales

Healtheon/WebMD Corporation           USA

Dr Yamada has an interest in 53,114 Ordinary Share ADRs of GlaxoSmithKline plc
(each ADR represents two Ordinary Shares in GlaxoSmithKline plc). 52,930 of
these ADRs were acquired prior to Dr Yamada being appointed to the Board of
GlaxoSmithKline plc. Dr Yamada also has an interest in 1,205,358 ADRs arising
from the grant of options under the Company's share option schemes, all of which
were granted prior to his appointment as a director.



Paragraph 6.F.2 (b) to (g) Financial Services Authority's Listing Rules

Dr Yamada has no details to disclose in respect of paragraph 6.F.2 (b) to (g) of
the Financial Services Authority's Listing Rules.



S M Bicknell

Company Secretary

14 January 2004


                      This information is provided by RNS
            The company news service from the London Stock Exchange